A four-drug regimen offers superior disease control and response depth in multiple myeloma compared to three-drug regimens. Adding monoclonal antibodies like Darzalex to standard treatments improves ...
Dr. Cesar Rodriguez presents findings from the phase 3 CARTITUDE-4 trial, which compared ciltacabtagene autoleucel (cilta-cel) with standard-of-care regimens in patients with relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results